AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome

RecruitingPhase 4Ages 18 Years - anyAllCenter For Sight
💬

In plain words

What the trial is, and whether it could suit you

This study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: Subjects must fulfill the following conditions to qualify for enrollment into the trial 1. Adults over 18 years old with a diagnosis of dry eye disease (DED) secondary to Sjögren's Syndrome within the past 2 years. 2. History of using or desiring artificial tears for DED symptoms within the past 2 months. 3. Unanesthetized Schirmer's Test (UA ST) score ≥1 and \< 10 mm/5 min and baseline total Corneal Fluorescein Staining (tCFS) score ≥2 and ≤ 15 (National Eye Institute, NEI, grading scale). Exclusion Criteria: Subjects with any of the following conditions on the eligibility exam may NOT be enrolled into the trial. 1. History of ocular surgery within the past 6 months. 2. Contact lens wear in either eye within 7 days of visit 1 (baseline) or use during study 3. On current topical treatment regimen for less than 3 months or anticipates any change to the regimen during the study period. 4. Use of topical steroid ocular medication or varenicline nasal spray within 4 weeks of baseline or during the study period. 5. Use of artificial tears within 2 hours prior to the baseline or study visit days. 6. Any known allergies to any component of the study drug. 7. Severe, uncontrolled autoimmune disease (e.g., rheumatoid arthritis, lupus). Uncontrolled is at the discretion of the PI. Subjects with severe systemic symptoms will not be included.
💊

What it tests

  • TRYPTYR (Acoltremon ophthalmic solution 0.003%)
📍

Where

1 site
Center For Sight
Venice, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy